Microbial (Pro)TGase

Microbial transglutaminase, production grade,
characterized for endotoxin, HCP, DNA, sterility


(MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis)

Order
Quantity
Price
Status
25 U 370 € available
10 x 25 U 2950 € available
20 x 25 U 5150 € available


Documents
Art. No. T153
Synonym EC 2.3.2.13; Protein-glutamine-γ-glutamyltransferase
Background info Microbial Transglutaminase (MTG) catalyzes the acyl transfer reaction between γ-carboxyamide groups of peptide bound glutamine residues and a variety or primary amines.
MTG can be used to covalently cross-link proteins with each other. Here, the ε-amino group of protein bound lysine serves as primary amine. However, MTG also accepts non-protein primary amines as substrate, e.g. amino-butane or amino-pentane.
Therefore, MTG can be used to attach primary-amine coupled functional markers like biotin, fluorescent dyes, click chemistry reagents or cytotoxins to proteins, e.g. antibodies.
Essentially, MTG is used for the production of antibody drug conjugates (ADCs).
Molecular Weight 38,333 Da (Dispase-activated MTG with N-terminal sequence: FRAPDSDDR...)
Source Recombinantly produced in E. coli.
No material of animal origin is used within production process.
Gene derived from Streptomyces mobaraensis.
Specific Activity > 25 U/mg
[One unit will catalyse the formation of 1 μmole of hydroxamate per min from Z-Gln-Gly-OH and hydroxylamine at pH 6.0 at 37°C, Grossowicz et al. (1950)]
Appearance White lyophilized solid
Reagents The purified transglutaminase is lyophilized from a solution in the following buffer: 50 mM NaOAc pH 5.0 + 0.3 M NaCl.
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves.
Reconstituted MTG solution might be turbid. However, MTG activity is not affected. In this case, centrifuge the solution and collect the supernatant.
After reconstitution, the solution should be stored frozen in working aliquots.
Application Labeling, immobilisation, conjugation and modification of proteins.
MTG can tolerate up to 10% DMSO in aqueous solutions without significant influence on its catalytic activity. A small activity loss of 4% was observed in the presence of 20% DMSO.
Storage Store working aliquots at ≤ - 20°C. Avoid repeated freezing and thawing.
Reference(s) Grossowicz et al., J. Biol. Chem. 1950, 187, 111-25
Ando et al., Agric. Biol. Chem. 1989, 53, 2613-17
Pasternack et al., Eur. J. Biochem. 1998, 257, 570-6
Pfleiderer et al., Microbiol. Res. 2005, 160, 265-71
Jeger et al., Angew. Chem. Int. Ed. Engl. 2010, 49, 9995-7
Kaufmann et al., Food Addit. Contam Part. A 2012, 29, 1364-73
Dennler et al., Bioconjugate Chem. 2014, 25, 569-78
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy